Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial

The LEADER Publication Committee on behalf of the LEADER Trial Investigators

Research output: Contribution to journalLetterpeer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial'. Together they form a unique fingerprint.